Gambaran Umum
Resverlogix Corp. is a biotechnology firm based in Canada, specializing in the development of innovative therapies primarily focusing on patients with cardiovascular disease, diabetes mellitus, and chronic kidney disease. At the core of its clinical development is apabetalone (RVX-208), a novel small molecule that regulates protein transcription to address severe unmet medical needs. Apabetalone is at the forefront of Resverlogix's projects, progressing through advanced clinical trials aimed at demonstrating its efficacy in reducing major adverse cardiac events. The company leverages its proprietary epigenetic platform technology that uniquely controls gene expression, emphasizing its commitment to leading-edge cardiovascular and epigenetic research to improve patient outcomes on a global scale.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai operating income untuk Resverlogix Corp. per 2025 Jun 30 adalah -4.82 MM.
- Nilai net income untuk Resverlogix Corp. per 2025 Jun 30 adalah -11.08 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | -4.82 | -11.08 | |
2025-03-31 | -4.61 | -13.98 | |
2024-12-31 | -4.60 | -7.63 | |
2024-09-30 | -4.27 | -11.23 | |
2024-06-30 | -4.32 | -10.74 | |
2024-03-31 | -4.70 | -10.25 | |
2023-12-31 | -5.18 | -16.74 | |
2023-09-30 | -5.37 | -12.82 | |
2023-06-30 | -6.48 | -10.04 | |
2023-03-31 | -7.08 | -6.43 | |
2022-12-31 | -11.43 | -3.61 | |
2022-09-30 | -15.77 | -21.31 | |
2022-06-30 | -18.79 | -24.92 | |
2022-03-31 | -20.15 | -27.12 | |
2021-12-31 | -15.94 | -24.77 | |
2020-12-31 | -14.57 | 2.46 | |
2020-10-31 | -12.75 | 3.77 | |
2020-07-31 | |||
2020-04-30 |
Laporan Laba Rugi: EPS
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | ||
2024-09-30 | -0.04 | -0.04 |
2024-06-30 | -0.04 | -0.04 |
2024-03-31 | -0.04 | -0.04 |
2023-12-31 | -0.06 | |
2023-09-30 | -0.05 | -0.05 |
2023-06-30 | -0.04 | -0.04 |
2023-03-31 | -0.02 | -0.03 |
2022-12-31 | -0.01 | |
2022-09-30 | -0.09 | -0.09 |
2022-06-30 | -0.10 | -0.10 |
2022-03-31 | -0.11 | -0.11 |
2021-12-31 | -0.10 | -0.10 |
2020-12-31 | 0.01 | 0.02 |
2020-10-31 | 0.02 | 0.02 |
2020-07-31 | 0.51 | 0.51 |
2020-04-30 | 0.57 | 0.54 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Resverlogix Corp. per 2025 Jun 30 adalah -2.96 MM.
- Nilai cash from investing activities untuk Resverlogix Corp. per 2025 Jun 30 adalah -0.45 MM.
- Nilai kas dari aktivitas pendanaan untuk Resverlogix Corp. per 2025 Jun 30 adalah 3.37 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -2.96 | -0.45 | 3.37 |
2025-03-31 | -3.00 | -0.36 | 3.46 |
2024-12-31 | -3.89 | -0.38 | 4.36 |
2024-09-30 | -3.93 | -0.43 | 4.31 |
2024-06-30 | -3.92 | -0.46 | 4.36 |
2024-03-31 | -3.73 | -0.49 | 4.28 |
2023-12-31 | -2.51 | -0.52 | 2.99 |
2023-09-30 | -1.66 | -0.52 | 2.26 |
2023-06-30 | -2.67 | -0.53 | 3.25 |
2023-03-31 | -3.03 | -0.54 | 3.11 |
2022-12-31 | -3.63 | -0.47 | 4.15 |
2022-09-30 | -4.06 | -0.37 | 4.06 |
2022-06-30 | -4.98 | -0.37 | 2.20 |
2022-03-31 | -9.03 | -0.93 | 10.44 |
2021-12-31 | -8.02 | -0.83 | 8.81 |
2020-12-31 | -4.40 | -0.43 | 4.95 |
2020-10-31 | -3.95 | -0.53 | 4.36 |
2020-07-31 | |||
2020-04-30 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2020-12-31 | |||
2020-10-31 | |||
2020-07-31 | |||
2020-04-30 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | ||
2024-09-30 | ||
2024-06-30 | ||
2024-03-31 | ||
2023-12-31 | ||
2023-09-30 | ||
2023-06-30 | ||
2023-03-31 | ||
2022-12-31 | ||
2022-09-30 | ||
2022-06-30 | ||
2022-03-31 | ||
2021-12-31 | ||
2020-12-31 | ||
2020-10-31 | ||
2020-07-31 | ||
2020-04-30 |
Efektivitas Manajemen
- roa untuk Resverlogix Corp. pada 2025 Jun 30 adalah -1.84.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -1.84 | ||||
2025-03-31 | -1.51 | ||||
2024-12-31 | -1.72 | ||||
2024-09-30 | -1.37 | ||||
2024-06-30 | -1.29 | ||||
2024-03-31 | -1.58 | ||||
2023-12-31 | -1.25 | ||||
2023-09-30 | -1.00 | ||||
2023-06-30 | -0.36 | ||||
2023-03-31 | -2.07 | ||||
2022-12-31 | -1.89 | ||||
2022-09-30 | -2.21 | ||||
2022-06-30 | -1.92 | ||||
2022-03-31 | 0.00 | ||||
2021-12-31 | 0.00 | 0.00 | |||
2020-12-31 | 0.18 | ||||
2020-10-31 | 5.43 | ||||
2020-07-31 | 5.43 | ||||
2020-04-30 | 7.25 |
Gross Margins
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2020-12-31 | |||
2020-10-31 | |||
2020-07-31 | |||
2020-04-30 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 1372821 |